Company profile
MARKER THERAPEUTICS, INC.
NASDAQ:MRKRBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ZEDENOLEUCEL | phase2 | — | 1 | terminated |
| NELDALEUCEL | phase1 | — | 1 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04511130 | phase2 | terminated | 2020-10-14 | 2024-03-01 | Marker Therapeutics, Inc. | Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant |
| NCT02978222 | phase2 | terminated | 2017-07-20 | 2020-01-15 | Marker Therapeutics, Inc. | Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer |
| NCT02593227 | phase2 | completed | 2016-04-01 | 2021-07-15 | Marker Therapeutics, Inc. | Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer |
| NCT06549751 | phase1 | not_yet_recruiting | 2026-07-16 | 2028-07-16 | Marker Therapeutics, Inc. | MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer |
| NCT05798897 | phase1 | recruiting | 2023-01-02 | 2028-02-28 | Marker Therapeutics, Inc. | Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma |
FDA applications (0)
No records yet.